Literature DB >> 36261786

Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.

Yang Yang1,2, Zhouyao Qian3, Mingyang Feng1,2, Weiting Liao1,2, Qiuji Wu1,2, Feng Wen1,2, Qiu Li4,5.   

Abstract

BACKGROUND: Few studies have demonstrated that the relationship between m6A-related genes and the prognosis, tumor microenvironment and drug resistance of LC.
METHODS: The main results were analyzed with bioinformatics methods.
RESULTS: Hence, we found 10 m6A-related genes expressed less in tumor samples in comparison with normal ones. Using consensus clustering, all LC patients were grouped into 2 subgroups according to the overall expression of 10 differential expressed m6A-related genes. In two clusters, the OS and immune characteristics were different. We analyzed the predictive potential of 10 m6A-related genes in the prognosis of LC, and obtained a risk prognosis model on the strength of ZC3H13, CBLL1, ELAVL1 and YTHDF1 as the hub candidate genes through LASSO cox. The expression of 4 hub m6A-related genes was validated by IHC in the HPA database. The infiltration level of dendritic cell, CD4+ T cell and neutrophil that were affected by CNV level of m6A-related genes in LUAD and LUSC patients. Moreover, based on GSCALite database, we found that LUSC patients with hypermethylation tended to have a better overall survival. In terms of drug sensitivity, etoposide correlated negatively with ELAVL1, HNRNPC, RBM15B, YTHDF2 and CBLL1. ZC3H13 had positively association with afatinib, while HNRNPC was positively associated with dasatinib, erlotinib, lapatinib and TGX221. Crizotinib had a negative correlation with ELAVL1, CBLL1, HNRNPC and RBM15B.
CONCLUSION: In conclusion, m6A-related genes are important participants in LC and the expression levels of ZC3H13, CBLL1, ELAVL1 and YTHDF1 are significant for prediction and treatment of LC. Researches of drug resistance based on m6A-related genes need to pay more attention for producing new therapeutic strategies of LC and CBLL1 may contribute to target treatment for further research.
© 2022. The Author(s).

Entities:  

Keywords:  Drug resistance; Genes; Immune; Lung cancer; Prognosis; m6A

Mesh:

Substances:

Year:  2022        PMID: 36261786      PMCID: PMC9583491          DOI: 10.1186/s12859-022-04984-5

Source DB:  PubMed          Journal:  BMC Bioinformatics        ISSN: 1471-2105            Impact factor:   3.307


  63 in total

1.  Selection of important variables and determination of functional form for continuous predictors in multivariable model building.

Authors:  Willi Sauerbrei; Patrick Royston; Harald Binder
Journal:  Stat Med       Date:  2007-12-30       Impact factor: 2.373

Review 2.  Lung Cancer 2020: Epidemiology, Etiology, and Prevention.

Authors:  Brett C Bade; Charles S Dela Cruz
Journal:  Clin Chest Med       Date:  2020-03       Impact factor: 2.878

3.  Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway.

Authors:  M V Blagosklonny; T Schulte; P Nguyen; J Trepel; L M Neckers
Journal:  Cancer Res       Date:  1996-04-15       Impact factor: 12.701

Review 4.  The epitranscriptome beyond m6A.

Authors:  David Wiener; Schraga Schwartz
Journal:  Nat Rev Genet       Date:  2020-11-13       Impact factor: 53.242

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

6.  YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation.

Authors:  Hao Sheng; Zhen Li; Shixin Su; Wenjing Sun; Xiaoya Zhang; Leilei Li; Jing Li; Shuangping Liu; Bin Lu; Shuai Zhang; Changliang Shan
Journal:  Carcinogenesis       Date:  2020-07-10       Impact factor: 4.944

7.  Dissecting the m6A methylation affection on afatinib resistance in non-small cell lung cancer.

Authors:  Qianqian Meng; Shuyuan Wang; Shunheng Zhou; Haizhou Liu; Xueyan Ma; Xu Zhou; Hui Liu; Chaohan Xu; Wei Jiang
Journal:  Pharmacogenomics J       Date:  2019-10-17       Impact factor: 3.550

8.  The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.

Authors:  Christina Demuth; Anne Tranberg Madsen; Britta Weber; Lin Wu; Peter Meldgaard; Boe Sandahl Sorensen
Journal:  BMC Cancer       Date:  2018-02-15       Impact factor: 4.430

Review 9.  Functions of N6-methyladenosine and its role in cancer.

Authors:  Liuer He; Huiyu Li; Anqi Wu; Yulong Peng; Guang Shu; Gang Yin
Journal:  Mol Cancer       Date:  2019-12-04       Impact factor: 27.401

Review 10.  m6 A RNA methylation: from mechanisms to therapeutic potential.

Authors:  P Cody He; Chuan He
Journal:  EMBO J       Date:  2021-01-20       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.